Myriad Genetics, Inc. (MYGN) recently announced results from a multi-year, real-world study that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight Psychotropic test. The study consisted of nearly 21,000 patients.Management expects to share additional study results later in 2024.The study’s latest positive initial outcome is a significant stepping stone for Myriad Genetics and is likely to boost the usage of its GeneSight Psychotropic test, part of i ...